GSK065   Click here for help

GtoPdb Ligand ID: 10358

Synonyms: GSK3335065 | inhibitor C1 [PMID: 28604669]
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: GSK065 (a.k.a. GSK3335065) was a clinical lead kynurenine-3-monooxygenase (KMO) inhibitor that was developed for potential to treat acute pancreatitis multiple organ dysfunction syndrome (AP-MODS) [1]. It was designed to be administered intravenously. The intention of inhibiting KMO is to return AP-MODS-associated elevation in 3-hydroxykynurenine levels [2] to the normal range, so as to reduce acute pancreatitis-induced organ damage. GSK065 was developed though a partnership between the University of Edinburgh's Centre for Inflammation Research and GSK's Discovery Partnerships with Academia programme.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 85.45
Molecular weight 346.07
XLogP 3.26
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(=O)CCc1noc2c1cc(Cl)c(c2)OC(c1ccccn1)C
Isomeric SMILES OC(=O)CCc1noc2c1cc(Cl)c(c2)O[C@@H](c1ccccn1)C
InChI InChI=1S/C17H15ClN2O4/c1-10(13-4-2-3-7-19-13)23-16-9-15-11(8-12(16)18)14(20-24-15)5-6-17(21)22/h2-4,7-10H,5-6H2,1H3,(H,21,22)/t10-/m1/s1
InChI Key WPAHVUADNLXSOM-SNVBAGLBSA-N
References
1. Hutchinson JP, Rowland P, Taylor MRD, Christodoulou EM, Haslam C, Hobbs CI, Holmes DS, Homes P, Liddle J, Mole DJ et al.. (2017)
Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase.
Nat Commun, 8: 15827. [PMID:28604669]
2. Skouras C, Zheng X, Binnie M, Homer NZ, Murray TB, Robertson D, Briody L, Paterson F, Spence H, Derr L et al.. (2016)
Increased levels of 3-hydroxykynurenine parallel disease severity in human acute pancreatitis.
Sci Rep, 6: 33951. [PMID:27669975]